

Salkeld J, Themistocleous Y *et al.*

22 **Abstract**

23 In endemic settings it is known that natural malaria immunity is gradually acquired following repeated 24 exposures. Here we sought to assess whether similar acquisition of blood-stage malaria immunity would 25 occur following repeated parasite exposure by controlled human malaria infection (CHMI). We report the 26 findings of a repeat homologous blood-stage *Plasmodium falciparum* (3D7 clone) CHMI study 27 (VAC063C; ClinicalTrials.gov NCT03906474). In total, 24 healthy, unvaccinated, malaria-naïve UK 28 adult participants underwent primary CHMI followed by drug treatment. Ten of these then underwent 29 secondary CHMI in the same manner, and then six of these underwent a final tertiary CHMI. As with 30 primary CHMI, malaria symptoms were common following secondary and tertiary infection, however, 31 most resolved within a few days of treatment and there were no long term sequelae or serious adverse 32 events related to CHMI. Despite detectable induction and boosting of anti-merozoite serum IgG antibody 33 responses following each round of CHMI, there was no clear evidence of anti-parasitic immunity 34 (manifest as reduced parasite growth *in vivo*) conferred by repeated challenge with the homologous 35 parasite in the majority of volunteers. However, three volunteers showed some variation in parasite 36 growth dynamics *in vivo* following repeat CHMI that were either modest or short-lived. We also observed 37 no major differences in clinical symptoms or laboratory markers of infection across the primary, 38 secondary and tertiary challenges. However, there was a trend to more severe pyrexia after primary 39 CHMI and the absence of a detectable transaminitis post-treatment following secondary and tertiary 40 infection. We hypothesize that this could represent the initial induction of disease tolerance or clinical 41 malaria immunity. Repeat homologous blood-stage CHMI is thus safe and provides a model with the 42 potential to further the understanding of the acquisition of blood-stage immunity in a highly controlled 43 setting.

44

Salkeld J, Themistocleous Y *et al.*

45 **Introduction**

46 Controlled human malaria infection (CHMI) is the most developed experimental human microbial 47 infection model. It has been critical to advancing new therapeutic drugs and vaccines, including the most 48 advanced anti-sporozoite vaccine for *Plasmodium falciparum*, RTS,S/AS01, and has provided key 49 insights into parasite immuno-biology and pathogenesis of disease (1). CHMI was pioneered in the 50 fascinating era of malariotherapy, in which deliberate malaria infection, delivered either via mosquito bite 51 or by blood transfusion, was administered as treatment for neurosyphilis prior to the availability of 52 penicillin in the mid-1940s (2). Since it was the induction of fever that led to improvement of 53 neurosyphilitic symptoms, patients were routinely re-challenged with both homologous and heterologous 54 strains (with *P. vivax* and to a lesser extent with *P. falciparum*) and this became the standard treatment of 55 neurosyphilis. Retrospective examinations of reinfection data in patients using homologous *P. vivax* or 56 homologous and/or heterologous *P. falciparum* demonstrated a reduction in fever episodes ("clinical 57 immunity") during the secondary infection as well as reductions in parasitaemia ("anti-parasitic 58 immunity"), suggesting some partial immunity can be conferred from one previous parasite exposure (3, 59 4). However, this phenomenon has not been re-explored by CHMI in the "modern era". 60 61 In the natural exposure setting (i.e. in malaria-endemic countries) the manifestations of severe malaria 62 disease vary with age and transmission setting (5). Nonetheless, immunity to severe malaria is gradually 63 acquired by young children following repeated infections with *P. falciparum*, and ultimately older 64 children and adults typically develop asymptomatic infections whereby they are able to tolerate much 65 higher levels of parasitaemia without symptoms or clinical signs of malaria (6). This naturally-acquired 66 immunity, observed in older children and adults, is widely understood to involve a complex interplay of 67 cellular and humoral immune mechanisms, and to develop over time, following repeated exposures, to 68 multiple parasite strains.

69

- 95 primary infection and the remainder of the secondary CHMI cohort. Indeed, one of these two volunteers 96 showed undetectable blood-stage infection out to 19 days.
- 97
- 98 Given natural immunity to the blood-stage parasite is slow to acquire, these findings after a single acute
- 99 primary exposure were not anticipated. However, they did suggest that repeat homologous blood-stage
- 100 CHMI could provide a model to further interrogate the immunological mechanisms that underlie the
- 101 acquisition of clinical and anti-parasitic immunity, which could then guide development of new
- 102 vaccination strategies. Here, we therefore sought to further develop this model by inviting these previous
- 103 participants back to take part in a final follow-on challenge study (called "VAC063C"), to enable the
- 104 assessment of safety and parasite growth dynamics following tertiary, secondary and primary homologous
- 105 blood-stage CHMI.

Salkeld J, Themistocleous Y *et al.*

106 **Results**

107 **Participant flow and demographics**

108 Twenty-five volunteers were screened for the VAC063C study. Sixteen of these were malaria-naïve

- 109 healthy adult volunteers, and the other nine volunteers were screened following invitation to participate,
- 110 after their previous enrolment and receipt of blood-stage *P. falciparum* CHMI as unvaccinated infectivity
- 111 controls in the VAC063 study (A and B CHMIs, ClinicalTrials.gov NCT02927145) (16) (**Figure 1A**).
- 112 Eleven volunteers were subsequently enrolled, comprising six volunteers who had previously undergone
- 113 two CHMIs in the VAC063 study (Group 1), two volunteers who had received a single prior CHMI
- 114 (Group 2) and a further three malaria-naïve volunteers to act as primary infectivity controls (Group 3).
- 115 Over the entire study period, only a single participant withdrew prior to completion (after 45 days of
- 116 follow-up post-CHMI) due to personal reasons. **Table S1** compares the demographics of those
- 117 undergoing primary, secondary or tertiary CHMI in the VAC063C study as well as the pooled
- 118 demographic data across all three CHMI studies (VAC063A, B and C). Age, gender, ethnicity and body
- 119 mass index (BMI) were comparable across all participants undergoing primary, secondary and tertiary
- 120 CHMI.

121

122 **Period of controlled human malaria infection**

Blood-stage CHMI, with the *P. falciparum* 3D7 clone, was initiated for the VAC063C study on 6th

124 November 2018; this was approximately 8 months after completion of the preceding VAC063B CHMI

125 (**Figure 1B**). Exactly as for VAC063A and VAC063B, the CHMI was initiated by administration of the

126 inoculum to each participant via an intravenous injection. This contained approximately 777 parasitised

127 erythrocytes in 5 mL of normal saline, as estimated by a limiting dilution assay of the inoculum (executed

- 128 as soon as the final participant had received it). This was highly comparable to the dose of approximately
- 129 452 and 857 parasitised erythrocytes administered to participants during the VAC063A and B CHMIs,
- 130 respectively (16). All eleven participants subsequently developed patent blood-stage parasitaemia and

Salkeld J, Themistocleous Y *et al.*

133

134 **Safety of repeat homologous** *P. falciparum* **CHMI**

135 There were no serious adverse events (SAEs) or unexpected reactions deemed possibly, probably or 136 definitely related to CHMI, blood draws or study drugs during the course of the VAC063C study and no 137 participants withdrew due to study-related adverse events (AEs). Otherwise, only a single SAE deemed 138 unrelated to study interventions occurred during VAC063C; abdominal pain secondary to suspected renal 139 calculus requiring overnight hospital admission. We next proceeded to analyse the safety data from the 140 VAC063C study alone, as well as data from all participants combined across the three VAC063 blood-141 stage CHMI trials. In total 24 participants underwent one CHMI only, 10 volunteers received two 142 homologous CHMIs and 6 received three homologous CHMIs. The intervals between the CHMI periods 143 were approximately 4 months (VAC063A to B) and 8 months (VAC063B to C) (**Figure 1B**).

144

145 The maximum severity reported and relative frequencies of CHMI-related solicited AEs for all 146 participants receiving primary, secondary and tertiary CHMI across the three CHMI studies are shown in 147 **Figure 2A,C**, with unsolicited AEs shown in **Table S2**. Data on solicited AEs from the VAC063C study 148 only are shown in **Figure 2B**. There were no major differences in the number or type of AE reported 149 across the primary, secondary and tertiary CHMI groups, although severe AEs were limited to those 150 undergoing primary or secondary CHMI (with the caveat that a smaller number of participants underwent 151 tertiary CHMI). The most commonly reported AEs were headache, fatigue, malaise, followed by 152 feverishness, chills, sweats, myalgia, nausea and arthralgia. A minority of volunteers reported diarrhoea 153 or vomiting. Maximum severity of AEs peaked between 24 and 48 hours post-diagnosis (after starting 154 antimalarial drug treatment) and most AEs had resolved within a few days of CHMI or completing 155 treatment with no long-term sequelae (**Figure 3**). A minority of participants also reported AEs possibly

Salkeld J, Themistocleous Y *et al.*

159 We next analysed the frequency and severity of objective clinical observations and laboratory AEs 160 (**Figure 4**, **Table S3**). We observed no differences in haemoglobin or platelet counts across the three 161 cohorts undergoing repeat *P. falciparum* infection. However, lymphocytopaenia was more frequent 162 following secondary and tertiary CHMI (affecting >60% participants) compared to <30% following 163 primary CHMI. There was also a trend toward less severe pyrexia with each successive CHMI (**Figure** 164 **4A,C**). In nearly all cases, these clinical changes were transient, coinciding with malaria diagnosis, with 165 pyrexia resolving within the next 48 hours and lymphocytes normalizing by 6 days post-treatment (T+6) 166 in VAC063C or by 28 days post-CHMI (C+28) in VAC063A and B (noting T+6 was not assessed in

168

167 these earlier studies).

169 During VAC063C we also noted a transaminitis occurring in Group 3 participants (those undergoing 170 primary CHMI), as measured by significantly raised alanine aminotransferase (ALT), one severe, at 6 171 days post-diagnosis and treatment (T+6) (**Figure 4B**); *P* = 0.03 by Kruskal-Wallis test. This was not 172 apparent in any participant undergoing secondary or tertiary CHMI. We potentially failed to observe this 173 degree of transamintis in the VAC063A and VAC063B cohorts because these studies did not include the 174 T+6 assessment (**Figure S2**), although four milder elevations of ALT were observed. Further examination 175 of the two volunteers with transaminitis in VAC063C revealed similar increases in aspartate 176 aminotransferase (AST) and gamma-glutamyl transferase (GGT), and that the participants had neither 177 signs nor symptoms of hepatitis. One participant reported mild loss of appetite and, upon examination, 178 mild epigastric and suprapubic tenderness were present but without right upper quadrant pain or 179 hepatosplenomegaly. Their AST normalised after 3 days and ALT after 12 days, although GGT did not 180 fully normalise until the last study visit (day C+90). The second participant remained completely

Salkeld J, Themistocleous Y *et al.*

206

Salkeld J, Themistocleous Y *et al.*

- 230 low levels of detectable lumefantrine in all samples remain unexplained but cannot explain the observed 231 parasite growth rates given their presence in all samples.
- 232

233 **Antibody responses following repeat homologous CHMI**

234 Finally, we assessed serum IgG antibody responses by ELISA to three commonly-studied merozoite

235 antigens – the 19 kDa C-terminus of merozoite surface protein 1 (MSP1 $_{19}$), apical membrane antigen 1

- 236 (AMA1) and reticulocyte-binding protein homologue 5 (RH5). MSP1₁₉-specific serum IgG responses
- 237 were detectable at day C+28 in >90% volunteers following initial CHMI. These were subsequently
- 238 boosted by each successive CHMI and were relatively well-maintained between parasite exposures
- 239 (**Figure 7A**). In contrast, serum IgG responses to AMA1 were less dominant after the primary CHMI
- 240 (with responses only detected in a minority of volunteers). These then boosted following repeat CHMI in
- 241 a similar manner to $MSP1_{19}$, however, these responses dropped back to baseline between each successive
- 242 *P. falciparum* exposure (**Figure 7B**). Responses to RH5 were undetectable in all volunteers at all time-
- 243 points tested (data not shown).
- 244
- 245 We also screened serum samples from all participants undergoing more than one CHMI for the presence 246 of red cell alloantibodies, which could have been raised by the repeated exposure to the blood-stage 247 inoculum. Samples were tested both at baseline (before primary CHMI) and at final follow-up (day C+90) 248 after the final (whether secondary or tertiary) CHMI. All tested samples were negative for alloantibodies 249 (data not shown).
- 250

Salkeld J, Themistocleous Y *et al.*

251 **Discussion**

252 This is the first assessment of repeat homologous *P. falciparum* blood-stage CHMI in the modern era, 253 where volunteers have reached diagnostic criteria before initiation of anti-malarial therapy. Overall we 254 have demonstrated that repeated exposure to homologous blood-stage parasites by CHMI is safe in 255 healthy adults, but does not lead to the development of any significant anti-parasitic blood-stage 256 immunity in the vast majority of re-challengees.

257

258 The frequencies of CHMI-associated solicited AEs were within expected ranges in all participants 259 undergoing a primary CHMI, consistent with previously reported studies of primary CHMI using both 260 blood-stage and sporozoite infection models (16-19). Inference about relative frequency of solicited AEs 261 in re-challenged participants is limited by relatively small sample size, selection bias of returning 262 participants and inter-subject variability in reporting of AEs, however, our findings suggest that there are 263 no major differences in the frequencies of AEs following homologous re-challenge, or any increased risk, 264 as compared to primary CHMI. The majority of AEs also resolve within a few days of treatment. 265 266 There were also no statistically significant differences in the frequencies of objective clinical or 267 laboratory markers of malaria infection across the repeat CHMIs, although we noted the highest levels of 268 pyrexia occurred in a subset of volunteers undergoing primary CHMI. This is not inconsistent with the 269 retrospective analyses of the old neurosyphilis treatment data (4) , although the key difference here is that 270 modern CHMIs only allow acute blood-stage infection prior to treatment in contrast to uncontrolled 271 parasitaemia which almost certainly led to more effective acquisition of anti-malarial clinical immunity. 272 We also noted the lowest lymphocyte counts occurred following secondary and tertiary infections. 273 Lymphocytopaenia following primary CHMI is well-documented, (20) although further migration of cells 274 from the periphery in repeat CHMI may reflect an immunological recall response upon secondary and

Salkeld J, Themistocleous Y *et al.*

275 tertiary infection, similar to our previous observations on antigen-specific B cells induced by subunit 276 blood-stage vaccination prior to CHMI (21).

277

278 We also detected a derangement in liver transaminases following primary CHMI in approximately 25% of 279 the participants (two in VAC063C and four in VAC063A and B), with the two in VAC063C of greatest 280 severity and noticeably occurring at six days post-treatment initiation. This has not been previously 281 observed in our centre, potentially due to lack of routine testing at the T+6 time point. Given that the 282 abnormalities rapidly improved, these AEs would not have been detected at later follow-up visits, raising 283 the possibility that frequency of liver function test (LFT) abnormalities post-primary CHMI may have 284 been previously underestimated. LFT abnormalities are known to occur in both naturally acquired and 285 experimental infection, and in blood-stage primary CHMI studies performed at QIMR, Australia, 286 moderate and severe elevations of transaminase elevations enzymes have been reported, peaking at 4-12 287 days after antimalarial treatment, with ALT/AST ratio >1 and normal bilirubin in both *P. falciparum* and 288 *P. vivax* infection models (22) . Our findings are consistent with this pattern and given timing of onset 289 and resolution, together with the observation that abnormal ALT levels normalise after treatment in 290 severe malaria, suggest the transaminitis is likely to relate directly to CHMI, with inflammation/infection 291 driving the ALT rather than the antimalarial drugs. However, since the transaminitis affected only a small 292 subset of the primary CHMI cohort, individual host factors may also have contributed. Importantly, all 293 ALT abnormalities were transient in nature, resolved spontaneously and were not associated with clinical 294 symptoms or any derangement of synthetic liver function, so these findings do not raise clinical concern 295 or preclude further testing using this repeat CHMI model, however, monitoring over similar time-points 296 in future studies is warranted. Moreover, we also saw no derangement in LFTs after secondary or tertiary 297 CHMI. We hypothesise that this could represent a degree of clinical immunity or immune "tolerance", 298 given transaminitis is a collateral marker of tissue damage. This is consistent with a modified $CD4^+$ T cell

Salkeld J, Themistocleous Y *et al.*

299 response after a single drug-treated infection that has since been demonstrated in further work using these 300 trial samples (23).

301

302 The blood-type of the donor of the red blood cells infected with 3D7 clone *P. falciparum* was Group O 303 Rhesus negative, and the volume administered for CHMI is extremely small, equivalent to only a few 304 microlitres of blood. As such, the risk of development of red cell alloantibodies following blood-stage 305 CHMI was deemed to be very low. Nevertheless, as an exploratory measure, participants who were re-306 challenged in the VAC063A, B and C studies, and therefore re-exposed to the same inoculum, were 307 retrospectively screened for IgG alloantibodies to red cells pre-CHMI and post their final follow-up. All 308 samples tested were negative for red cell alloantibodies, consistent with single CHMI data from other 309 groups using the same challenge inoculum (James McCarthy, personal communication). These data also 310 suggest that an antibody response against the challenge inoculum itself was not a confounding factor in 311 these re-challenge studies, which is also consistent with the very similar parasite growth kinetics observed 312 in the majority of re-challengees.

313

314 Across the repeat CHMIs, all participants developed patent parasitaemia and reached diagnostic criteria, 315 with the exception of the one participant who failed to reach diagnosis after secondary CHMI. By and 316 large, our data suggest minimal to no acquisition of effective anti-parasitic blood-stage immunity occurs 317 following one or two drug-treated and acute exposures to *P. falciparum*, even when using the homologous 318 parasite clone. This is not inconsistent with observations from natural infection in the field, albeit here 319 exposure to heterologous parasite strains will occur and blood-stage parasitaemias are likely to reach 320 higher levels prior to treatment. This is also in stark contrast to the highly effective pre-erythrocytic 321 immunity afforded by repeat exposure to sporozoite CHMI under drug cover (24, 25). We nonetheless 322 were able to observe the priming and boosting of antibody responses to the well-studied merozoite 323 antigens MSP119 and AMA1, but not RH5. This hierarchy of immuno-dominance of *de novo* antibody

Salkeld J, Themistocleous Y *et al.*

329

330 Nonetheless, we did note three participants of interest whose PMR varied across the repeat CHMIs. In 331 one volunteer parasites grew consistently slowly, in another a modest reduction in PMR was seen upon 332 secondary CHMI, and finally one volunteer showed a dramatic suppression of growth following 333 secondary CHMI that was not repeated following tertiary CHMI. We could identify no demographic or 334 obvious host factors to explain these observations, and these three volunteers had no history of prior 335 malaria exposure. The latter participant's only abnormality on blood tests was the development of a 336 moderate anaemia by 28 days post-secondary CHMI, and their haemoglobin immediately preceding 337 CHMI had been borderline low (111 g/dL). The relationship between iron status and malaria is complex 338 (29) but it is unlikely that a short-term moderate anaemia would have caused such significant suppression 339 of parasite growth. This is also supported by the fact that when a tertiary infection was administered the 340 participant's haemoglobin dropped again to similar levels but parasite growth conversely thrived. Also no 341 systemic supplemental iron was known to be taken at the time of CHMI that could explain the increased 342 growth rate. Instead, the highly anomalous PMR seen after secondary infection might be explained by one 343 or more of the following: i) the induction and then waning of an effective immune response, or the 344 induction of a highly specific immune response against a variant surface antigen on the infected red blood 345 cell that was only expressed by the parasite during the secondary CHMI; ii) surreptitious or accidental 346 self-treatment with a drug with an antimalarial effect; or iii) an operator error in the administration of the 347 secondary challenge inoculum. The latter would seem unlikely, because even if inoculated with a single 348 parasite, with 10-fold blood-stage growth every 48 hours, this would not lead to such prolonged qPCR

Salkeld J, Themistocleous Y *et al.*

359 **Methods**

360 **Study Design and Participants**

361 VAC063C was a non-blinded blood-stage *P. falciparum* controlled human malaria infection (CHMI) 362 study to evaluate the safety and parasite growth dynamics of primary, secondary and tertiary blood-stage 363 *P. falciparum* CHMI of healthy malaria-naïve UK adults. Healthy, malaria-naïve and non-pregnant adults 364 aged 18-50 were invited to participate in the study. Volunteers were recruited and challenged at the 365 Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), part of the Oxford Vaccine Centre 366 (OVC) at the University of Oxford. Eleven volunteers were enrolled in total. A full list of inclusion and 367 exclusion criteria is reported in **Supplementary Methods**. Allocation to study group (Groups 1 and 2) 368 was based on previous involvement and CHMI exposure in the VAC063 trial (ClinicalTrials.gov 369 NCT02927145) (16), with new malaria-naïve volunteers comprising Group 3. The primary endpoint of 370 the study was safety of repeat homologous CHMI (as measured by active and passive collection of 371 clinical and laboratory AEs after each CHMI) and qPCR-derived parasite multiplication rate (PMR) was 372 the primary endpoint for the assessment of parasite growth dynamics. 373 374 Data were pooled for analysis from participants who were enrolled in both VAC063C (November 2018) 375 and in two previous CHMI studies under the preceding VAC063 protocol – VAC063A (November 2017) 376 and VAC063B (March 2018). Briefly, the VAC063 protocol encompassed VAC063A and VAC063B, 377 and was an open label, non-randomised Phase I/IIa clinical trial evaluating vaccine efficacy of the 378 recombinant blood stage malaria protein RH5.1 in $AS01_B$ adjuvant (16). The VAC063C trial was

379 conducted to investigate the durability of any protective anti-parasite immunity measured in control (non-

380 vaccinated) participants upon homologous re-challenge for the second or third time.

381

Salkeld J, Themistocleous Y *et al.*

382 **Study Oversight**

383 The VAC063C study was designed and conducted in the UK at the CCVTM, University of Oxford. The 384 study was registered on ClinicalTrials.gov (NCT03906474) and received ethical approval from the UK 385 National Health Service Research Ethics Services (South Central – Oxford A reference 18/SC/0521). All 386 participants provided written informed consent and consent was verified before each CHMI. The study 387 was conducted according to the principles of the current revision of the Declaration of Helsinki 2008 and 388 in full conformity with the ICH guidelines for Good Clinical Practice (GCP). GCP compliance was 389 independently and externally monitored by the Clinical Trials and Research Governance (CTRG) Team at 390 the University of Oxford. Details of the previous VAC063 study approvals and oversight (from which 391 primary and secondary CHMI data were used for a pooled analysis) are as previously described (16). 392

393 **Controlled Human Malaria Infection**

394 The blood samples used as infectious inocula in this study were produced by Drs Gregor Lawrence, Allan 395 Saul and colleagues at QIMR in Brisbane, Australia in 1994 and consist of aliquots of *P. falciparum* 396 (clone 3D7) infected erythrocytes taken from a single donor (31). Blood was collected at the Australian 397 Red Cross Blood Bank in an aseptic manner using standard blood bank equipment. The leukocytes were 398 removed with a leukocytic filter. The thawing and washing of the cells reduced the amount of serum 399 transferred with the red cells by a factor of 1000, compared to injecting the same volume of blood. The 400 red cells were cryopreserved using a protocol from the American Association of Blood Banks Technical 401 Manual that is normally employed for freezing blood from patients and donors with rare blood groups. 402 The blood group of the donor was group O and Rhesus negative, Kell antigen negative. To date, CHMI of 403 malaria-naïve individuals using this inoculum has always resulted in parasitaemia as detected by qPCR 404 and/or microscopy (17, 19, 31, 32).

Salkeld J, Themistocleous Y *et al.*

425 risk of participants being diagnosed prematurely, without any impact on participant safety. Participants

426 were treated with a course of artemether/lumefantrine (Riamet) at diagnosis (n=9), or where

427 contraindicated, with a course of atovaquone/proguanil (Malarone) (n=2). Half of the Riamet doses and

428 all Malarone doses were directly observed by study investigators. After completion of treatment, follow-

429 up visits were conducted at 6 days post-diagnosis/treatment (T+6), as well as at 28, 45 and 90 days post-

Salkeld J, Themistocleous Y *et al.*

- 430 CHMI (C+28, C+45 and C+90). This was similar though not identical to the follow-up schedule for 431 VAC063A and B CHMIs where a T+6 visit was not included.
- 432

433 **Safety Analysis**

434 Participants were reviewed once on day 1 post-challenge and twice-daily from day 2. At each visit they

435 were asked a list of symptoms commonly associated with malaria infection ('solicited' symptoms

436 including feverishness, malaise, fatigue, arthralgia, back pain, headache, myalgia, chills, rigors, sweats,

437 headache, nausea, vomiting and diarrhoea). The severity of any reported symptom was then graded by the

438 participant from 1 (mild) to 3 (severe), using the severity grading criteria shown in **Supplementary**

439 **Material**. These were all recorded by the investigator as solicited AEs if they occurred during the 28 day

440 period post-CHMI (or until completion of antimalarial treatment). Pyrexia was scored as follows: absent

441 (\leq 37.5°C), mild (37.6 - 38.2°C), moderate (38.3 - 38.9°C) and severe (\geq 39°C) and participants were also

442 asked to measure and record their temperature in a diary card if they experienced feverishness outside of

443 their clinic visit. Blood samples for full blood count and biochemistry were obtained prior to CHMI (C-1)

444 and then at C+6, diagnosis, T+6, C+45 and C+90. These were evaluated at Oxford University Hospitals

445 NHS Trust providing 5-part differential white cell counts and quantification of electrolytes, urea,

446 creatinine, bilirubin, alanine aminotransferase (ALT), alkaline phosphatase (ALP) and albumin. Blood

447 was also tested serologically for evidence of Hepatitis B, Hepatitis C, HIV, EBV and CMV infection prior

448 to CHMI. Blood tests were carried out at other time-points if clinically indicated.

449

450 All other (unsolicited) AEs were collected until day 90 post-CHMI and their likely causality in relation to 451 CHMI or antimalarial drugs assessed and assigned a MedDRA code as described in the protocol. All AEs 452 considered possibly, probably or definitely related to CHMI/antimalarial drugs were reported (**Table S2**), 453 and all laboratory AEs at least possibly related to study interventions are also reported (**Table S3**).

454

Salkeld J, Themistocleous Y *et al.*

455 **qPCR and PMR Modelling**

Salkeld J, Themistocleous Y *et al.*

- 480 for comparison. The antimalarial compounds tested included amodiaquine, artemisinin, atovaquone,
- 481 chloroquine, clindamycin, doxycycline, lumefantrine, mefloquine, proguanil, pyrimethamine, quinine,
- 482 and sulfadoxine.
- 483

484 **Statistical Analysis**

- 485 Data were analysed using GraphPad Prism version 9.3.1 for Windows (GraphPad Software Inc.,
- 486 California, USA). Statistical tests used are reported in the Results text, and included two-tailed Kruskal-
- 487 Wallis test with Dunn's multiple comparison post-test, and log-rank analysis (Mantel Cox) of the Kaplan
- 488 Meier curves. A value of *P* < 0.05 was considered significant.

Salkeld J, Themistocleous Y *et al.*

489 **Author Contributions**

- 490 Conceived and performed the experiments: YT, JRB, CHM, TAR, ROP, MMH, BK, NJE, CMN, DMS,
- 491 FAB, WN, RLR, MB, FR-L, PMF, DQ, KJE, IDP, PJS, SES, SJD, AMM
- 492 Analyzed the data: JS, YT, SES, JRB, NJE, SJD, AMM.
- 493 Project Management: JSC, FLN.
- 494 Wrote the paper: JS, YT, SES, SJD, AMM.

495

496

497 **Acknowledgments**

498 The authors are grateful for the assistance of Natalie Lella and Michelle Kuskova for recruitment 499 activities, Daniel Marshall Searson for database management, Julie Furze for laboratory assistance, and 500 Richard Morter, Amy Flaxman and Duncan Bellamy for qPCR support (Jenner Institute, University of 501 Oxford); Amy Duckett and Carly Banner for arranging contracts (University of Oxford); James McCarthy 502 for providing the 3D7 inoculum (QIMR, Australia); Amy Noe (Leidos Life Sciences) and Lorraine 503 Soisson (U.S. Agency for International Development, USAID) for useful discussions; William Dennis 504 and Chau Vuong (WRAIR, USA) for assisting with the antimalarial drug testing; and all the study 505 volunteers. The VAC063 clinical trial was funded by the Office of Infectious Diseases, Bureau for Global 506 Health, USAID, under the terms of Malaria Vaccine Development Program (MVDP) contract AID-OAA-507 C-15-00071, for which Leidos, Inc. was the prime contractor. The opinions expressed here are those of 508 the authors and do not necessarily reflect the views of the USAID. This work was also supported in part 509 by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The 510 views expressed are those of the authors and not necessarily those of the NIHR or the Department of 511 Health and Social Care. TAR held a Wellcome Trust Research Training Fellowship [108734/Z/15/Z] and

Salkeld J, Themistocleous Y *et al.*

- 512 CMN held a Wellcome Trust Sir Henry Wellcome Postdoctoral Fellowship [209200/Z/17/Z]. SJD is a
- 513 Jenner Investigator and held a Wellcome Trust Senior Fellowship [106917/Z/15/Z].

514

515 **Conflict of Interest Statement**

516 All other authors have declared that no conflict of interest exists.

517 **Data and Materials Availability**

518 Requests for materials should be addressed to the corresponding author.

Salkeld J, Themistocleous Y *et al.*

519 **References**

- 520 1. Roestenberg M, Hoogerwerf MA, Ferreira DM, Mordmuller B, Yazdanbakhsh M. Experimental
- 521 infection of human volunteers. Lancet Infect Dis. 2018;18(10):e312-e22.
- 522 2. Snounou G, Perignon JL. Malariotherapy--insanity at the service of malariology. Advances in 523 parasitology. 2013;81:223-55.
- 524 3. Collins WE, Jeffery GM, Roberts JM. A retrospective examination of reinfection of humans with 525 Plasmodium vivax. Am J Trop Med Hyg. 2004;70(6):642-4.
- 526 4. Collins WE, Jeffery GM. A retrospective examination of secondary sporozoite- and trophozoite-
- 527 induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity

528 following secondary infection. Am J Trop Med Hyg. 1999;61(1 Suppl):20-35.

- 529 5. Griffin JT, Hollingsworth TD, Reyburn H, Drakeley CJ, Riley EM, Ghani AC. Gradual
- 530 acquisition of immunity to severe malaria with increasing exposure. Proc Biol Sci.
- 531 2015;282(1801):20142657.
- 532 6. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than 533 answers. Nat Immunol. 2008;9(7):725-32.
- 534 7. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N, et al. Immunity 535 to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. The 536 Lancet. 2002;360(9333):610-7.
- 537 8. Edstein MD, Kotecka BM, Anderson KL, Pombo DJ, Kyle DE, Rieckmann KH, et al. Lengthy 538 antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration.
- 539 Antimicrob Agents Chemother. 2005;49(10):4421-2.
- 540 9. Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, et al. Protective
- 541 CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat 542 Commun. 2013;4:2836.
- 543 10. Dunachie SJ, Walther M, Vuola JM, Webster DP, Keating SM, Berthoud T, et al. A clinical trial
- 544 of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine. 545 2006;24(15):2850-9.
- 546 11. Rampling T, Ewer KJ, Bowyer G, Bliss CM, Edwards NJ, Wright D, et al. Safety and High Level
- 547 Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus
- 548 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. J Infect Dis.
- 549 2016;214(5):772-81.

- 582 23. Diana Muñoz Sandoval FB, Wiebke Nahrendorf, Alasdair Ivens, Michalina Mazurczyk, Yrene
- 583 Themistocleous, Sarah E. Silk, Jordan R. Barrett, Nick J. Edwards, Giorgio Napolitani, Angela M.
- 584 Minassian, Simon J. Draper, Philip J. Spence. Adaptive T cells regulate disease tolerance in human
- 585 malaria. 2021. MedRXiv. doi.org/10.1101/2021.08.19.21262298
- 586 24. Bijker EM, Bastiaens GJ, Teirlinck AC, van Gemert GJ, Graumans W, van de Vegte-Bolmer M,
- 587 et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is
- 588 mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A. 2013;110(19):7862-7.
- 589 25. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, et al. Protection
- 590 against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009;361(5):468-77.
- 591 26. Hodgson SH, Llewellyn D, Silk SE, Milne KH, Elias SC, Miura K, et al. Changes in Serological
- 592 Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection. Front
- 593 Microbiol. 2016;7:1604.
- 594 27. Biswas S, Choudhary P, Elias SC, Miura K, Milne KH, de Cassan SC, et al. Assessment of
- 595 Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization,
- 596 Controlled Human Malaria Infection and Natural Exposure. PLoS One. 2014;9(9):e107903.
- 597 28. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss GE, et al. A prospective
- 598 analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein
- 599 microarray. Proc Natl Acad Sci U S A. 2010;107(15):6958-63.
- 600 29. Spottiswoode N, Duffy PE, Drakesmith H. Iron, anemia and hepcidin in malaria. Front 601 Pharmacol. 2014;5:125.
- 602 30. Minassian AM, Themistocleous Y, Silk SE, Barrett JR, Kemp A, Quinkert D, et al. Controlled
- 603 human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly. JCI 604 Insight. 2021;6(23).
- 605 31. Cheng Q, Lawrence G, Reed C, Stowers A, Ranford-Cartwright L, Creasey A, et al.
- 606 Measurement of *Plasmodium falciparum* growth rates in vivo: a test of malaria vaccines. The American
- 607 journal of tropical medicine and hygiene. 1997;57(9347970):495-500.
- 608 32. Stanisic DI, Liu XQ, De SL, Batzloff MR, Forbes T, Davis CB, et al. Development of cultured
- 609 Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of
- 610 anti-malaria drugs and vaccines. Malar J. 2015;14(1):143.
- 611 33. Douglas AD, Edwards NJ, Duncan CJ, Thompson FM, Sheehy SH, O'Hara GA, et al.
- 612 Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates
- 613 During Controlled Human Malaria Infection. J Infect Dis. 2013;208(2):340-5.

- 614 34. Duncan CJ, Sheehy SH, Ewer KJ, Douglas AD, Collins KA, Halstead FD, et al. Impact on
- 615 Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-
- 616 C1/Alhydrogel+CPG 7909. PLoS One. 2011;6(7):e22271.
- 617 35. Sheehy SH, Spencer AJ, Douglas AD, Sim BK, Longley RJ, Edwards NJ, et al. Optimising
- 618 Controlled Human Malaria Infection Studies Using Cryopreserved Parasites Administered by Needle and
- 619 Syringe. PLoS One. 2013;8(6):e65960.
- 620
- 621
- 622
- 623
- 624
-
- 625

Salkeld J, Themistocleous Y *et al.*

626 **Figure Legends**

627 **Figure 1. VAC063C flow chart of study design and volunteer recruitment.**

- 628 **(A)** Enrolment into the VAC063C study began in October 2018. Twenty five volunteers were screened
- 629 for eligibility. Eleven eligible volunteers were identified, six of whom were VAC063 participants
- 630 returning for a tertiary controlled human malaria infection (CHMI) (Group 1), two of whom were
- 631 VAC063 participants returning for a secondary CHMI (Group 2) and three of whom were newly enrolled
- 632 participants for primary CHMI (Group 3). Clinical follow-up continued until 90 days after challenge
- $($ C+90) and was completed by $14th$ January 2019. Volunteer demographics are summarized in **Table**
- 634 **S1**. **(B)** In total (across three CHMI studies, VAC063A, B and C) 24 participants underwent primary
- 635 CHMI, 10 of whom subsequently underwent secondary CHMI and six of those participants returned for a
- 636 tertiary CHMI. The first CHMI (VAC063A) was on $14th$ November 2017, the second (VAC063B) was on

637 6th March 2018 and the third (VAC063C) was on $6th$ November 2018.

638

639 **Figure 2. Safety of repeated** *P. falciparum* **blood-stage CHMI.**

640 Participants were asked about the presence of 13 solicited systemic adverse events (AE) at study each 641 visit following CHMI. (**A**) The maximum severity of any solicited AE reported by each participant in the 642 48 hours before and after diagnosis during primary (n=24), secondary (n=10) and tertiary (n=6) CHMI is 643 shown as a proportion of the total number of participants. (**B**) VAC063C: The solicited AEs recorded 644 during the CHMI period are shown as the maximum severity reported by each participant and as a 645 proportion of the participants reporting each individual AE for primary ($n=3$), secondary ($n=2$) and 646 tertiary (n=6) CHMI. AE data was collected until 90 days after challenge. Colour coding as per panel 647 A. (**C**) The solicited AEs recorded during the CHMI period are shown as the maximum severity reported 648 by each participant and as a proportion of the participants reporting each individual AE for primary 649 (n=24), secondary (n=10) and tertiary (n=6) CHMI for all participants across the three CHMI studies. 650 Groups refer to specific study group numbers in VAC063A, B and C. Colour coding as per panel A.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.06.27.22276860;](https://doi.org/10.1101/2022.06.27.22276860) this version posted June 28, 2022. The copyright holder for this preprint

Salkeld J, Themistocleous Y *et al.*

651

652 **Figure 3. Symptom evolution during repeated** *P. falciparum* **blood-stage CHMI.**

653 The maximum severity of any solicited systemic adverse events (AE) recorded at the indicated time 654 points during the CHMI period for each participant for primary $(n=24)$, secondary $(n=10)$ and tertiary 655 (n=6) CHMI.

656

657 **Figure 4. Objective measurements and laboratory AEs during repeated** *P.* 658 *falciparum* **blood-stage CHMI.**

659 (**A**) Frequency and severity of pyrexia, anaemia, thrombocytopaenia and lymphopaenia during primary

660 (n=24), secondary (n=10) and tertiary (n=6) CHMI from screening until 90 days post-CHMI. (**B**) Alanine

661 aminotransferase (ALT) for each participant in VAC063C at each timepoint for primary $(n=3)$, secondary

662 (n=2) and tertiary (n=6) CHMI showing significant transaminitis after treatment of the primary infection

 (663) $(P = 0.03$ as calculated by Kruskal-Wallis test of peak ALT values). Dashed lines show the local cut off

664 for Grade 1, 2 and 3 abnormalities. Time is number of days post-CHMI, except for day of diagnosis

665 (DoD) and day 6 post-treatment (T+6) which vary by participant. The same information for VAC063 A

666 and B (which did not include a T+6 assessment) is presented in **Figure S2**. (**C**) Maximum recorded

667 temperature during primary (n=24), secondary (n=10) and tertiary (n=6) CHMI. Individual data points

668 and the median are shown. Dashed lines show the local cut off for Grade 1, 2 and 3 abnormalities.

669 Kruskal-Wallis test showed no significant difference between primary, secondary and tertiary CHMI (*P* =

670 0.31). (**D**) Median haemoglobin concentration and lymphocyte count for all participants across

671 VAC063A, B and C over time for primary $(n=24)$, secondary $(n=10)$ and tertiary $(n=6)$ CHMI (of which

 672 n=18 were female and n=22 male). Time points are the same as in panel B. Kruskal-Wallis test showed

673 no significant difference between primary, secondary and tertiary CHMI (minimum haemoglobin

674 concentration $P = 0.93$; minimum lymphocyte count $P = 0.19$).

675

Salkeld J, Themistocleous Y *et al.*

676 **Figure 5. Parasite growth dynamics following repeated** *P. falciparum* **blood-stage CHMI.**

677 (**A**) qPCR data for primary (n=24), secondary (n=10) and tertiary (n=6) CHMI across the VAC063A, B

- 678 and C studies. Parasitaemia measured by qPCR over time in parasites/mL (p/mL) blood is shown for each
- 679 volunteer. CHMI was initiated by intravenous inoculation of *P. falciparum* infected erythrocytes on day
- 680 0. The lower limit of quantification is indicated by the dotted line at 20 p/mL; values below this level are
- 681 plotted for information only. (**B**) Median qPCR data are shown for primary, secondary and tertiary CHMI.
- 682 Colours as in panel A. (C) Parasitaemia at the time of diagnosis. Individual data points and the median \pm
- 683 inter-quartile range for primary (n=24), secondary (n=9) and tertiary (n=6) CHMI are shown. Note one
- 684 participant requested antimalarial treatment at day C+20 during secondary CHMI without reaching the
- 685 diagnostic criteria so no data point is shown for this participant. *P* value as calculated by Kruskal-

686 Wallis test showed no significant difference between groups. (**D**) Kaplan-Meier plot of time to diagnosis

687 in days. Note one secondary CHMI participant requested treatment and was censored at day C+20. Log-

688 rank (Mantel-Cox) test showed no significant difference in time to diagnosis between primary, secondary

689 and tertiary CHMI. (**E**) The parasite multiplication rate (PMR) per 48 hours was modelled from the qPCR

690 data up until the time point of diagnosis. Individual data points and median \pm inter-quartile range for

691 primary, secondary and tertiary CHMI PMR are shown. *P* value as calculated by Kruskal-Wallis test

692 showed no significant difference.

693

694 **Figure 6. Individual variation in parasite growth dynamics of repeated** *P.* 695 *falciparum* **blood-stage CHMI.**

696 qPCR data for primary (blue), secondary (pink) and tertiary (purple) CHMI. Parasitaemia is shown over 697 time for each volunteer who underwent more than one CHMI (total $n=10$). The PMR per 48 hours was 698 modelled from the qPCR data up until the time point of diagnosis for each participant for each CHMI and 699 is shown below the relevant parasite growth graph. (**A**) Data from participants who showed minimal 700 variation in parasite growth dynamics between each CHMI (n=7 for primary and secondary CHMI, of

Salkeld J, Themistocleous Y *et al.*

713 Individual data points and median are shown.

B

